- Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection
-
Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, Kang DH, Song GA, Cho M
- KMID: 1782219
- Korean J Hepatol.
- 2010 Mar;16(1):38-48.
- doi: 10.3350/kjhep.2010.16.1.38
BACKGROUND/AIMS: The combination therapy of peginterferon (PEG-IFN) and ribavirin is the standard treatment for hepatitis C virus (HCV) infection. However, few trials have involved patients with cirrhosis. The purpose of... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
-
Kim JH, Han KH, Lee KS, Park YN, Ahn SH, Chon CY, Moon YM
- KMID: 1777167
- Yonsei Med J.
- 2006 Dec;47(6):793-798.
- doi: 10.3349/ymj.2006.47.6.793
Combination therapy with interferon alpha (IFN- alpha) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%.... -
- CITED
-
- Close
- SHARE
-
- Close
- Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
-
Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ
- KMID: 2164362
- Clin Mol Hepatol.
- 2015 Jun;21(2):125-130.
- doi: 10.3350/cmh.2015.21.2.125
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the... -
- CITED
-
- Close
- SHARE
-
- Close
